Frontiers in Oncology | Cancer Immunity and Immunotherapy

Original Research

Published on 09 Feb 2023

A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanoma

in Cancer Immunity and Immunotherapy

Ann W. Silk
Brendan Curti
Jennifer Bryan
Tracie Saunders
Weichung Shih
Michael P. Kane
Phoebe Hannon
Christopher Fountain
Jessica Felcher
Andrew Zloza

Frontiers in Oncology

doi 10.3389/fonc.2023.1108341

3,625 views
7 citations

Original Research

Published on 09 Feb 2023

Combinatory analysis of immune cell subsets and tumor-specific genetic variants predict clinical response to PD-1 blockade in patients with non-small cell lung cancer

in Cancer Immunity and Immunotherapy

Nikita Dutta
Anna Rohlin
Ella A. Eklund
Maria K. Magnusson
Frida Nilsson
Levent M. Akyürek
Per Torstensson
Volkan I. Sayin
Anna Lundgren
Andreas Hallqvist

Frontiers in Oncology

doi 10.3389/fonc.2022.1073457

3,156 views
4 citations

Original Research

Published on 02 Feb 2023

Interim result of phase II, prospective, single-arm trial of long-course chemoradiotherapy combined with concurrent tislelizumab in locally advanced rectal cancer

in Cancer Immunity and Immunotherapy

Jiale Gao
Xiao Zhang
Zhengyang Yang
Jie Zhang
Zhigang Bai
Wei Deng
Guangyong Chen
Rui Xu
Qi Wei
Yishan Liu

Frontiers in Oncology

doi 10.3389/fonc.2023.1057947

3,485 views
17 citations

Review

Published on 02 Feb 2023

Tumor−associated macrophage polarization in the inflammatory tumor microenvironment

in Cancer Immunity and Immunotherapy

Zijuan Zou
Hongfen Lin
Mengsen Li
Bo Lin

Frontiers in Oncology

doi 10.3389/fonc.2023.1103149

10,203 views
46 citations

Review

Published on 31 Jan 2023

Interleukin-34 and immune checkpoint inhibitors: Unified weapons against cancer

in Cancer Immunity and Immunotherapy

Fadhl Alshaebi
Mohammed Safi
Yousif A. Algabri
Mahmoud Al-Azab
Abdullah Aldanakh
Mohammed Alradhi
Alariqi Reem
Caiqing Zhang

Frontiers in Oncology

doi 10.3389/fonc.2023.1099696

4,051 views
8 citations

Original Research

Published on 31 Jan 2023

A novel prognostic model related to oxidative stress for treatment prediction in lung adenocarcinoma

in Cancer Immunity and Immunotherapy

Haijun Peng
Xiaoqing Li
Yanchao Luan
Changjing Wang
Wei Wang

Frontiers in Oncology

doi 10.3389/fonc.2023.1078697

2,988 views
4 citations

Case Report

Published on 30 Jan 2023

Combined NK-CIK and PD-1 inhibitor (nivolumab), an effective immunotherapy for treating intrahepatic lymphoepithelioma-like cholangiocarcinoma unassociated with EBV infection: Two case reports and a literature review

in Cancer Immunity and Immunotherapy

Alen Sam Saji
Biao Yang
Wan Ting Hou
Xia Liu
Qiu Ping Ren
Yuan Feng Wei
Yu Zu Zhang
Xi Yang

Frontiers in Oncology

doi 10.3389/fonc.2023.1090580

2,116 views
5 citations

Case Report

Published on 27 Jan 2023

STK11 loss and SMARCB1 deficiency mutation in a dedifferentiated lung cancer patient present response to neo-adjuvant treatment with pembrolizumab and platinum doublet: A case report

in Cancer Immunity and Immunotherapy

Jianxin Chen
Junhui Wang

Frontiers in Oncology

doi 10.3389/fonc.2023.1088534

2,433 views
5 citations

Review

Published on 27 Jan 2023

Cyclooxygenase-2-Prostaglandin E2 pathway: A key player in tumor-associated immune cells

in Cancer Immunity and Immunotherapy

Kaipeng Jin
Chao Qian
Jinti Lin
Bing Liu

Frontiers in Oncology

doi 10.3389/fonc.2023.1099811

18,489 views
88 citations

Original Research

Published on 27 Jan 2023

Tumor regression rate, PD-L1 expression, pembrolizumab/nab-paclitaxel–based regimens, squamous cell carcinoma, and comorbidities were independently associated with efficacy of neoadjuvant chemoimmunotherapy in non-small cell lung cancer

in Cancer Immunity and Immunotherapy

Xingsheng Hu
Chunhong Hu
Xianling Liu
Fang Ma
Junpeng Xie
Ping Zhong
Chenxi Tang
Dan Fan
Yuan Gao
Xiang Feng

Frontiers in Oncology

doi 10.3389/fonc.2022.1057646

3,832 views
6 citations

Original Research

Published on 26 Jan 2023

A novel cuproptosis-related LncRNA signature: Prognostic and therapeutic value for low grade glioma

in Cancer Immunity and Immunotherapy

Jun Wen
Wenting Zhao
Xiaolei Shu

Frontiers in Oncology

doi 10.3389/fonc.2022.1087762

3,716 views
7 citations

Original Research

Published on 26 Jan 2023

SHP-2-induced M2 polarization of tumor associated macrophages via IL-4 regulate colorectal cancer progression

in Cancer Immunity and Immunotherapy

Zhihan Li
Jinchuan Xi
Baokun Li
Youqiang Liu
Guiying Wang
Bin Yu
Hongqing Ma
Zhilin Li
Zhenya Zhang

Frontiers in Oncology

doi 10.3389/fonc.2023.1027575

3,283 views
6 citations

Review

Published on 25 Jan 2023

Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer

in Cancer Immunity and Immunotherapy

Yurong Peng
Zhuo Li
Yucheng Fu
Yue Pan
Yue Zeng
Junqi Liu
Chaoyue Xiao
Yingzhe Zhang
Yahui Su
Guoqing Li

Frontiers in Oncology

doi 10.3389/fonc.2023.1011810

8,068 views
13 citations

Mini Review

Published on 24 Jan 2023

Targeting the cMET pathway to enhance immunotherapeutic approaches for mUM patients

in Cancer Immunity and Immunotherapy

Devayani Machiraju
Jessica C. Hassel

Frontiers in Oncology

doi 10.3389/fonc.2022.1068029

3,036 views
3 citations

Review

Published on 24 Jan 2023

Microenvironment and the progress of immunotherapy in clinical practice of NSCLC brain metastasis

in Cancer Immunity and Immunotherapy

Mengqing Xie
Chunxia Su

Frontiers in Oncology

doi 10.3389/fonc.2022.1006284

3,431 views
5 citations

Original Research

Published on 23 Jan 2023

MMP11 is associated with the immune response and immune microenvironment in EGFR-mutant lung adenocarcinoma

in Cancer Immunity and Immunotherapy

Lu Bai
Ran Huo
Guotao Fang
Tiantian Ma
Yanhong Shang

Frontiers in Oncology

doi 10.3389/fonc.2023.1055122

3,268 views
9 citations